Discontinued — last reported Q4 '23
North America Specialty — Goodwill, Impaired, Accumulated Impairment Loss
Viatris North America Specialty — Goodwill, Impaired, Accumulated Impairment Loss decreased by 67.8% to $124M in Q4 2023 compared to the prior quarter. Over 2 years (FY 2020 to FY 2023), North America Specialty — Goodwill, Impaired, Accumulated Impairment Loss shows a downward trend with a -43.2% CAGR. This is a positive signal — lower values indicate better performance for this metric.
Analysis
How to read this metric
An increase indicates that the company has recognized significant write-downs due to underperformance or diminished future earnings expectations for assets within the North American specialty segment. A stable figure suggests that the carrying value of these assets remains supported by current business performance.
Detailed definition
This metric represents the cumulative total of impairment charges recognized against goodwill specifically allocated to...
Peer comparison
Peers in the pharmaceutical industry often report similar impairment losses when acquired product lines or business units fail to meet original growth projections, making this a standard indicator of M&A integration success.
vtrs_segment_north_america_specialty_goodwill_impaired_accumulated_impairment_lossHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '23 | |
|---|---|---|---|---|---|---|---|
| Value | $385M | $385M | $385M | $385M | $385M | $385M | $124M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | -67.8% |
| YoY Change | — | — | — | — | +0.0% | +0.0% | — |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Viatris's north america specialty — goodwill, impaired, accumulated impairment loss?
- Viatris (VTRS) reported north america specialty — goodwill, impaired, accumulated impairment loss of $124M in Q4 2023.
- What is the long-term trend for Viatris's north america specialty — goodwill, impaired, accumulated impairment loss?
- Over 2 years (2020 to 2023), Viatris's north america specialty — goodwill, impaired, accumulated impairment loss has grown at a -43.2% compound annual growth rate (CAGR), from $385M to $124M.
- What does north america specialty — goodwill, impaired, accumulated impairment loss mean?
- The total historical loss in value recorded for goodwill associated with the North American specialty drug business.